Work that speaks
for itself.

THE CHALLENGE

A leading European biotech required a robust, submission-ready Budget Impact Model to support the reimbursement and national immunisation programme negotiations for its tick-borne encephalitis (TBE) vaccine across multiple European markets. Existing internal models were insufficiently granular for payer scrutiny, and the timeline to submission was tight. The client needed a model that could be adapted efficiently for each target market without rebuilding from scratch.

WHAT WE DELIVERED

• Core global BIM framework adaptable across five European markets
• Epidemiological base layer — TBE incidence, hospitalisation rates, and at-risk population sizing by geography
• Current vaccination coverage and competing product market share modelling
• Uptake curve scenarios across a 5-year time horizon
• Full cost offset analysis — averted hospitalisations, ICU admissions, and long-term sequelae
• One-way and scenario sensitivity analyses across key payer uncertainty drivers
• Submission-ready technical report and model documentation for each market

THE CHALLENGE

A global pharmaceutical company developing a transformative therapy for sickle cell disease needed a rigorous Cost of Illness model to underpin its global market access strategy. Existing published literature was fragmented and inconsistent across geographies, and the client needed a robust, credible evidence base that could support payer conversations in the UK, Germany, France, and the US simultaneously — framing both the clinical and economic burden of a condition that remains significantly underserved.

WHAT WE DELIVERED

• Systematic literature review of direct and indirect cost evidence across target markets
• Direct medical costs — acute VOC hospitalisations, chronic complications, transfusions, chelation therapy, and outpatient management
• Indirect costs — productivity loss, absenteeism, presenteeism, and early workforce exit
• Informal carer costs — unpaid carer time and associated economic impact
• Health-related quality of life burden mapped to published EQ-5D utility values
• Cost per patient per year estimates by disease severity and geography
• Scenario modelling comparing current burden against optimised treatment pathways

THE CHALLENGE

A clinical-stage biotech developing a novel CAR-T cell therapy engaged Altima Partners to build its market access evidence base ahead of anticipated regulatory approval. With a first-in-class mechanism, limited long-term survival data, and a small but well-defined patient population, the modelling challenge was significant — requiring a framework that could credibly extrapolate clinical trial data, withstand HTA scrutiny, and be adapted efficiently for NICE, G-BA, and HAS submissions from a single core model.

WHAT WE ARE DELIVERING

• Epidemiological model — eligible patient population sizing across UK, Germany, and France
• Partitioned survival model using phase II trial data with extrapolation scenario analysis
• Health state utility mapping from trial-collected EQ-5D data
• NHS and European cost inputs including administration, monitoring, and AE management
• Comparative effectiveness analysis against current standard of care
• Budget Impact Model for NHS England and integrated care system level
• Full HTA-ready documentation package for NICE submission